Velthorst E, Koeter M, van der Gaag M, Nieman D H, Fett A-K J, Smit F, Staring A B P, Meijer C, de Haan L
Academic Medical Center,Department of Psychiatry, Amsterdam,The Netherlands.
Parnassia Psychiatric Institute,The Hague,The Netherlands.
Psychol Med. 2015 Feb;45(3):453-65. doi: 10.1017/S0033291714001147. Epub 2014 May 22.
There is an increasing interest in cognitive-behavioural therapy (CBT) interventions targeting negative symptoms in schizophrenia. To date, CBT trials primarily focused on positive symptoms and investigated change in negative symptoms only as a secondary outcome. To enhance insight into factors contributing to improvement of negative symptoms, and to identify subgroups of patients that may benefit most from CBT directed at ameliorating negative symptoms, we reviewed all available evidence on these outcomes.
A systematic search of the literature was conducted in PsychInfo, PubMed and the Cochrane register to identify randomized controlled trials reporting on the impact of CBT interventions on negative symptoms in schizophrenia. Random-effects meta-analyses were performed on end-of-treatment, short-term and long-term changes in negative symptoms.
A total of 35 publications covering 30 trials in 2312 patients, published between 1993 and 2013, were included. Our results showed studies' pooled effect on symptom alleviation to be small [Hedges' g = 0.093, 95% confidence interval (CI) -0.028 to 0.214, p = 0.130] and heterogeneous (Q = 73.067, degrees of freedom = 29, p < 0.001, τ 2 = 0.081, I 2 = 60.31) in studies with negative symptoms as a secondary outcome. Similar results were found for studies focused on negative symptom reduction (Hedges' g = 0.157, 95% CI -0.10 to 0.409, p = 0.225). Meta-regression revealed that stronger treatment effects were associated with earlier year of publication, lower study quality and with CBT provided individually (as compared with group-based).
The co-occurring beneficial effect of conventional CBT on negative symptoms found in older studies was not supported by more recent studies. It is now necessary to further disentangle effective treatment ingredients of older studies in order to guide the development of future CBT interventions aimed at negative symptom reduction.
针对精神分裂症阴性症状的认知行为疗法(CBT)干预措施越来越受到关注。迄今为止,CBT试验主要聚焦于阳性症状,仅将阴性症状的变化作为次要结果进行研究。为了更深入了解导致阴性症状改善的因素,并确定可能从旨在改善阴性症状的CBT中获益最大的患者亚组,我们回顾了关于这些结果的所有现有证据。
在PsychInfo、PubMed和Cochrane注册库中对文献进行系统检索,以确定报告CBT干预对精神分裂症阴性症状影响的随机对照试验。对阴性症状的治疗结束时、短期和长期变化进行随机效应荟萃分析。
纳入了1993年至2013年间发表的共35篇文献,涵盖2312例患者的30项试验。我们的结果显示,以阴性症状为次要结果的研究中,研究对症状缓解的合并效应较小[Hedges' g = 0.093,95%置信区间(CI)-0.028至0.214,p = 0.130]且具有异质性(Q = 73.067,自由度 = 29,p < 0.001,τ 2 = 0.0捌1,I 2 = 60.31)。聚焦于阴性症状减轻的研究也得到了类似结果(Hedges' g = 0.157,95% CI -0.10至0.409,p = 0.225)。元回归分析显示,更强的治疗效果与更早的发表年份、更低的研究质量以及个体提供的CBT(与基于团体的相比)相关。
近期研究不支持早期研究中发现的传统CBT对阴性症状的同时有益效果。现在有必要进一步理清早期研究中有效的治疗成分,以指导未来旨在减轻阴性症状的CBT干预措施的开发。